EZH2 and breast cancer: Among them, the HGF/c-MET pathway is closely related to cancer metastasis and can promote breast cancer resistance to tamoxifen through the EZH2/HOTAIR-MIR-141/200A feedback signaling pathway (Lai et al., 2025).